-
公开(公告)号：EP3935060A1
公开(公告)日：2022-01-12
申请号：EP20708488.0
申请日：2020-03-03
申请人： Astrazeneca AB
发明人： KETTLE, Jason, Grant , SIMPSON, Iain , PHILLIPS, Christopher , BOYD, Scott , STEWARD, Oliver, Ross , BODNARCHUK, Michael, Steven , CASSAR, Doyle, Joseph , PIKE, Kurt, Gordon
IPC分类号： C07D498/04 , A61P35/00 , C07D487/04 , C07D498/14 , C07D498/22 , A61K31/553
-
公开(公告)号：EP3683220A1
公开(公告)日：2020-07-22
申请号：EP20156172.7
申请日：2016-09-15
申请人： Astrazeneca AB
发明人： PIKE, Kurt, Gordon , BARLAAM, Bernard Christophe , HUNT, Thomas Anthony , EATHERTON, Andrew John
IPC分类号： C07D471/04 , A61K31/4745 , A61P25/28 , A61P35/00
摘要： The specification generally relates to compounds of Formula (I) :
and pharmaceutically acceptable salts thereof, where R 1 , R 2 , R 3 , R 4 and R 5 have any of the meanings defined herein, for use in the treatment of Huntington's disease.-
公开(公告)号：EP3440079A1
公开(公告)日：2019-02-13
申请号：EP17714741.0
申请日：2017-03-30
申请人： Astrazeneca AB
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
-
4.发明授权MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K 有权在与mTOR激酶和/或在与PI3K应用MORPHOLINOPYRIMIDINDERIVATE相关疾病
公开(公告)号：EP2176238B1
公开(公告)日：2012-04-18
申请号：EP08776183.9
申请日：2008-07-08
申请人： AstraZeneca AB
发明人： PIKE, Kurt, Gordon
IPC分类号： C07D239/42 , A61K31/505 , A61P9/00 , A61P11/00 , A61P29/00 , A61P35/00
CPC分类号： C07D239/42
摘要： A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
-
公开(公告)号：EP1928874A1
公开(公告)日：2008-06-11
申请号：EP06779396.8
申请日：2006-09-12
申请人： AstraZeneca AB
发明人： CAULKETT, Peter, William, Rodney , MCKERRECHER, Darren , NEWCOMBE, Nicholas, John , PIKE, Kurt, Gordon , ROBB, Graeme, Richard , WARING, Michael, James
IPC分类号： C07D471/04 , C07D487/04 , A61K31/437 , A61K31/4985 , A61P3/10
CPC分类号： C07D471/04 , C07D487/04
摘要： Compounds of Formula (I) wherein R1 to R11, A and X1 to X3 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
-
公开(公告)号：EP1689741B1
公开(公告)日：2008-02-13
申请号：EP04798661.7
申请日：2004-11-25
申请人： AstraZeneca AB
IPC分类号： C07D405/12 , A61K31/443 , A61K31/445 , A61P3/10
CPC分类号： C07D405/12
摘要： Compounds of Formula (I) wherein: R1-X- is selected from: methyl, methoxymethyl and Formula (X); R2 is selected from hydrogen, methyl, chloro and fluoro; n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.
-
公开(公告)号：EP3371183A1
公开(公告)日：2018-09-12
申请号：EP16790601.5
申请日：2016-11-02
申请人： Astrazeneca AB
发明人： PIKE, Kurt, Gordon , BARLAAM, Bernard, Christophe , HUNT, Thomas, Anthony , EATHERTON, Andrew, John
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
CPC分类号： A61K31/4745 , A61K31/282 , A61K31/407 , A61K31/704 , A61K33/24 , A61K45/06 , A61K2121/00 , A61K2300/00 , A61P35/00 , C07D471/04
摘要： The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
-
8.发明公开MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K 有权在与mTOR激酶和/或在与PI3K应用MORPHOLINOPYRIMIDINDERIVATE相关疾病
公开(公告)号：EP2176238A1
公开(公告)日：2010-04-21
申请号：EP08776183.9
申请日：2008-07-08
申请人： AstraZeneca AB
发明人： PIKE, Kurt, Gordon
IPC分类号： C07D239/42 , A61K31/505 , A61P9/00 , A61P11/00 , A61P29/00 , A61P35/00
CPC分类号： C07D239/42
摘要： A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
-
9.发明公开TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开三取代嘧啶衍生物用于治疗增生性疾病
公开(公告)号：EP2074118A2
公开(公告)日：2009-07-01
申请号：EP08776181.3
申请日：2008-07-08
申请人： AstraZeneca AB
IPC分类号： C07D413/14 , C07D417/14 , A61K31/5377 , A61P35/00 , C07D413/04
CPC分类号： C07D413/14 , C07D413/04 , C07D417/14
摘要： A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
-
10.发明公开2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS 审中-公开2-苯基咪唑[4,5B]吡啶/吡嗪和嘌呤衍生物ALS GLUCOKINASEMODULATOREN
公开(公告)号：EP1891069A1
公开(公告)日：2008-02-27
申请号：EP06727138.7
申请日：2006-05-19
申请人： AstraZeneca AB
发明人： CAULKETT, Peter, William, Rodney , MCKERRECHER, Darren , NEWCOMBE, Nicholas, John , PIKE, Kurt, Gordon , WARING, Michael, James
IPC分类号： C07D473/00 , C07D471/04 , C07D487/04 , A61K31/437 , A61P3/08
CPC分类号： C07D471/04 , C07D473/00 , C07D487/04
摘要： Compounds of Formula (I), wherein R1- R10, A and X1 to X3 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.045 秒)
